Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Ainara Soria et al.|The Lancet|2018Cited by 1.7k
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A. Reiss, Yara Abdou, Mathew G. Angelos et al.|Nature Medicine|2025Cited by 189
KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.Ravindra Uppaluri, Douglas R. Adkins, Nancy Y. Lee et al.|Journal of Clinical Oncology|2019Cited by 51